Monitoring for cytomegalovirus and Epstein-Barr virus infection in chronic lymphocytic leukemia patients receiving i.v. fludarabine-cyclophosphamide combination and alemtuzumab as consolidation therapy

The combination of fludarabine and cyclophosphamide (FC) has become the standard of care in chronic lymphocytic leukemia (CLL) patients. Due to the well-recognized F-related immunosuppression,[1][1] a higher risk of opportunistic infections could be expected by adding another immunosuppressive agent

[1]  F. Baldanti,et al.  Monitoring human cytomegalovirus infection in transplant recipients. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[2]  T Hamblin,et al.  Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial , 2007, The Lancet.

[3]  M. Grever,et al.  Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Hallek,et al.  Due to low infection rates no routine anti‐infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine‐based first line therapy , 2007, British journal of haematology.

[5]  M. Keating,et al.  Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. , 2006, Clinical lymphoma & myeloma.

[6]  J. Gribben,et al.  Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  G. Brittinger,et al.  Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. , 2005, Blood.

[8]  P. Ueland,et al.  Automated assay for the determination of methylmalonic acid, total homocysteine, and related amino acids in human serum or plasma by means of methylchloroformate derivatization and gas chromatography-mass spectrometry. , 2005, Clinical chemistry.

[9]  D. Catovsky,et al.  Richter's transformation of chronic lymphocytic leukemia. The possible role of fludarabine and the Epstein-Barr virus in its pathogenesis. , 2005, Leukemia research.

[10]  R. Gräsbeck,et al.  Hereditary juvenile cobalamin deficiency caused by mutations in the intrinsic factor gene. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Ashley P Ng,et al.  Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation. , 2005, Haematologica.

[12]  E. Nexo,et al.  Nonradioactive Vitamin B 12 Absorption Test Evaluated in Controls and in Patients with Inherited Malabsorption of Vitamin B 12 , 2005 .

[13]  E. Nexo,et al.  Holo-transcobalamin concentration and transcobalamin saturation reflect recent vitamin B12 absorption better than does serum vitamin B12. , 2004, Clinical chemistry.

[14]  A. Chapelle,et al.  Genetically heterogeneous selective intestinal malabsorption of vitamin B12: Founder effects, consanguinity, and high clinical awareness explain aggregations in Scandinavia and the Middle East , 2004, Human mutation.

[15]  S. Barutça,et al.  Oral versus intramuscular cobalamin treatment in megaloblastic anemia: a single-center, prospective, randomized, open-label study. , 2003, Clinical therapeutics.

[16]  A. Ho,et al.  Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia , 2003, British journal of haematology.

[17]  F. Baldanti,et al.  The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders , 1999, British journal of haematology.

[18]  J. Ritz,et al.  Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling , 1999, Nature Medicine.

[19]  R. Allen,et al.  Effective treatment of cobalamin deficiency with oral cobalamin. , 1998, Blood.

[20]  G. Schilirò,et al.  Efficacy of oral administration of high-dose cobamamide in a patient with Imerslund-Gräsbeck syndrome. , 1996, Pediatric hematology and oncology.

[21]  E. Podell,et al.  Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. , 1988, The New England journal of medicine.

[22]  R. Berlin,et al.  Oral treatment of pernicious anemia with high doses of vitamin B12 without intrinsic factor. , 2009, Acta medica Scandinavica.